Stock 600993 MAYINGLONG PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Mayinglong Pharmaceutical Group Co., LTD.

Equities

600993

CNE000001HN2

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-16 pm EDT 		5-day change 1st Jan Change
29.35 CNY -0.98% Intraday chart for Mayinglong Pharmaceutical Group Co., LTD. +1.24% +21.38%
Apr. 19 Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 17 Mayinglong Pharmaceutical Receives Registration Approval for New Colorectal Treatment MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Mayinglong Pharmaceutical Receives Registration Approval for New Colorectal Treatment
MT
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Hangzhou Yunbai Pharmaceutical Technology Co., Ltd. agreed to acquire 86.816% of stake in Shenzhen Daphne Pharmaceautical Co.,Ltd from from Mayinglong Pharmaceutical Group Co., LTD., Huayi Development Co., Ltd., China Bao An Co., Ltd and Guofa Jianfu Industrial Co., Ltd. for approximately CNY 260 million.
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
CI
Mayinglong Pharmaceutical Group Co., Ltd. Announces Cash Dividend for the Year 2019, Payable on July 30, 2020
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600993 Stock
  4. News Mayinglong Pharmaceutical Group Co., LTD.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW